Effect of Obesity, Serum Lipoproteins, and Apolipoprotein E Genotypes on Mortality in Hospitalized Elderly Patients

Filomena Addante, M.D.,¹ Daniele Sancarlo, M.D.,¹ Massimiliano Copetti, M.Sc.,² Carlo Scarcelli, M.D.,¹ Maria Grazia Longo, M.D.,¹ Valeria Niro, M.D.,¹ Giulia Paroni, B.D., Ph.D.,¹ Fabio Pellegrini,^{2,3} Luigi Fontana, M.D., Ph.D.,⁴ and Alberto Pilotto, M.D.¹

Abstract

Background: The aim of this study was to investigate the relationship among apolipoprotein E (APOE) polymorphism, body mass index (BMI), and dyslipidemia and how these factors modify overall mortality in a cohort of hospitalized elderly patients.

Methods: Plasma concentrations of total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), BMI, and APOE genotype were evaluated in 1,012 hospitalized elderly patients, who were stratified into three groups according to their baseline BMI and APOE allele status. Multivariate logistic regression analysis was used to assess whether APOE genotype, BMI, and dyslipidemia are associated with mortality, adjusting for potential confounders. Interaction analysis was also performed.

Results: Obese patients have significantly higher levels of TC and LDL-C compared to normal-weight and overweight subjects, for both sexes. APOE $\epsilon 4$ carriers have significantly higher levels of TC and LDL-C compared with $\epsilon 2$ and $\epsilon 3$ carrier both in males and females. Interaction analysis showed that women with TC < 180 mg/dL, LDL-C < 100 mg/dL, normal weight, and $\epsilon 3$ carrier (odds ratio [OR] = 3.42, 95% confidence interval [CI] 1.36–8.60) and men with LDL-C < 100 mg/dL, HDL-C < 40 mg/dL, and $\epsilon 3$ carrier (OR = 1.97, 95% CI 1.04–3.74) were at highest risk of mortality.

Conclusions: In elderly hospitalized patients, obesity and APOE genotype influence the lipid profile and mortality risk. A significant interaction among BMI, dyslipidemia, and APOE genotype was observed that could identify elderly patients with different risks of mortality.

Introduction

EXCESSIVE BODY WEIGHT IS associated at all ages with detrimental changes in the lipid profile. Higher body mass index (BMI), a surrogate measurement of total body fat, is associated with higher plasma concentrations of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and triglycerides (TG).¹ Data from several epidemiological studies have also shown that apolipoprotein E (APOE) polymorphism is associated with variation of serum TC and LDL-C concentrations.^{2,3} APOE is a multifunctional glycoprotein that plays a key role in regulating lipoprotein metabolism and cardiovascular risk.⁴ The APOE gene exhibits a

genetic polymorphism with three common alleles ($\epsilon 2$, $\epsilon 3$, and $\epsilon 4$), which encode for three protein isoforms E2, E3, and E4.⁵ APOE polymorphism has been related to significant modifications of the lipoprotein profile, with the $\epsilon 2$ allele being associated with lower and the $\epsilon 4$ allele with higher TC and LDL-C levels than the $\epsilon 3$ allele.^{6,7} Isoform-specific effects include the association of APOE $\epsilon 4$ with increased risk for atherosclerosis, stroke, impaired cognitive function, and Alzheimer disease (AD).^{7,8–10} Moreover, some^{11,12} but not all, population-based studies^{13,14} have found a negative or positive association between mortality risk and APOE $\epsilon 2$ and APOE $\epsilon 3$ polymorphisms, respectively. However, to the best of our knowledge, no study has investigated the interaction

¹Geriatric Unit & Gerontology-Geriatrics Research Laboratory, Department of Medical Sciences, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.

²Unit of Biostatistics, Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.

³Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, S.Maria Imbaro (CH), Italy.

⁴Division of Nutrition and Aging, Istituto Superiore di Sanità, Rome, Italy and Division of Geriatrics and Nutritional Science, Washington University in St. Louis, Missouri.

between APOE polymorphism, BMI, and dyslipidemia in a large cohort of hospitalized elderly patients, in whom the aging process and co-morbidity may have profound effects on body composition and lipid metabolism.

The purpose of the present study was to evaluate the relationship among APOE polymorphism, adiposity, and dyslipidemia in a large group of elderly patients who were admitted to our hospital. A second aim was to study how these factors affect prognosis by modifying overall mortality.

Methods

Study design

From January, 2006, to March, 2007, all patients consecutively admitted to the Geriatrics Unit of the "Casa Sollievo della Sofferenza" Hospital, IRCCS, San Giovanni Rotondo, Italy, were screened for inclusion in the study. Inclusion criteria were: (1) Caucasian race, (2) age ≥ 65 years; (3) ability to provide an informed consent or availability of a proxy for informed consent. Exclusion criteria were: (1) Diagnosis of neoplasms; (2) medical/surgical hospitalization within 1 month before the study; (3) use of lipid-lowering drugs during the previous 4 weeks. Patients with AD were included in the study. Diagnoses of possible/probable AD were made according to the criteria of the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association Work Group (NINDS-ADRDA).¹⁵ This study was approved by the Human Studies Committee of "Casa Sollievo della Sofferenza" Hospital, IRCCS, San Giovanni Rotondo, Italy, and all subjects gave informed consent before their participation.

All measurements were performed during the hospital admission examination. Height was measured without shoes to the nearest 0.1 cm. Body weight was obtained on a balance scale in the morning after subjects fasted for 12 h overnight. BMI was calculated by dividing body weight (in kilograms) by the square of height (in meters). According to the National Institutes of Health (NIH) guidelines, normal weight was defined as a BMI ≥ 18.5 and ≤ 24.9 kg/m², overweight as a BMI ≥ 25 and ≤ 29.9 kg/m², and obesity as a BMI ≥ 30 kg/m².¹⁶

Information on the vital status of the participants was obtained at regular intervals from the municipal population registries located in the towns where the patients resided at the time of hospital admission. Mortality data were available up to January 31, 2009.

Laboratory analysis

A venous blood sample was taken to determine lipid and lipoprotein concentrations, and APOE genotypes after subjects had fasted for at least 12 h. Plasma levels of TC, TG, LDL-C, and high-density lipoprotein cholesterol (HDL-C) were measured by standardized enzymatic procedures and expressed in mg/dL.

Genetic analysis

Genomic DNA was purified manually from peripheral blood by organic protein extraction and ethanol precipitation according to a standard method. The APOE genotypes were determined by polymerase chain reaction (PCR) and agarose gel electrophoresis as described previously.¹⁷ Briefly, a

combination of four specific primers in three different pairs sharing the same stringent PCR conditions was used. Allele-specific primers were: ASP1, CGG ACA TGG AGG ACG TGT; ASP2, CGG ACA TGG AGG ACG TGC; ASP3, CTG GTA CAC TGC CAG GCG; and ASP4, CTG GTA CAC TGC CAG GCA, synthesized by Invitrogen (Invitrogen Corporation, Carlsbad, CA). The primer pair ASP-1/ASP-4 identifies the $\epsilon 2$ allele, the primer pair ASP-1/ASP-3 identifies the $\epsilon 3$ allele, and the primer pair ASP-2/ASP-3 identifies the $\epsilon 4$ allele. On an Applied Biosystems GeneAmp PCR System 9700, the amplification conditions were 94°C for 2 min, followed by 32 cycles at 96°C for 15 sec, 61°C for 30 sec, and 72°C for 30 sec. Reaction buffer included 1.5 U of *Taq* DNA polymerase (Platinum[®]*Taq*, Invitrogen, Carlsbad, CA), 10 pmoles of each primer, 100 picomoles (PM) nucleoside triphosphates (NTPs), and 1 mM MgCl₂. The presence/absence of specific allele PCR products detected by electrophoresis analysis on a 2% agarose gel identified the six APOE genotypes. Patients were classified into the following three phenotype groups: APOE $\epsilon 2$, $\epsilon 3$, and $\epsilon 4$ groups. The $\epsilon 3/\epsilon 3$ genotype was the reference category; subjects with the $\epsilon 2/\epsilon 2$ or $\epsilon 2/\epsilon 3$ genotypes were considered $\epsilon 2^+$ carriers and subjects with $\epsilon 3/\epsilon 4$ or $\epsilon 4/\epsilon 4$ genotypes were considered $\epsilon 4^+$ carriers. Subjects who were carriers of the $\epsilon 2/\epsilon 4$ genotype were excluded from the analysis.

Statistical analysis

Patients' baseline characteristics were reported as mean $\pm$ standard deviation (SD) or frequencies and percentages for continuous and categorical variables, respectively. Baseline comparison between men and women was made using the chi-squared test for categorical variables and the Mann-Whitney U-test for continuous variables. Baseline differences according to BMI groups and APOE alleles groups were assessed with the analysis of variance (ANOVA) F-test or chi-squared test for continuous and categorical variables, respectively. *p* values for trend were estimated using the Mantel-Haenszel chi-squared test and ANOVA F-test for trend, appropriately. Genotype distribution according to the Hardy-Weinberg equilibrium was analyzed by the exact chi-squared test.

Multivariate logistic regression analysis was performed to investigate, separately, the association between BMI, dyslipidemia, APOE polymorphism, and all-cause mortality. The following cutoffs were used to dichotomize dyslipidemia variables: 180 mg/dL for TC, 100 mg/dL for LDL-C, 150 mg/dL for TG, 40 mg/dL for HDL-C in men, and 50 mg/dL for HDL-C in women. Results were shown and odds ratio (OR) along their 95% confidence interval (95% CI).

Furthermore, to evaluate interactions among covariates and identify distinct and homogeneous subgroups of patients in terms of mortality, the REPCAM method was used.¹⁸ This tree-based method integrates the advantages of main-effects logistic regression and tree-growing techniques. At each partitioning step, the method chooses the covariate and its best binary split to maximize the difference in the outcome of interest. The algorithm stops when user-defined conditions (stopping rules) are met. To obtain a more robust and stable split, a permutation approach was adopted to choose the best splitting variable. Global adjustment for age, diabetes, AD, and cardiovascular diseases was accounted for.

All analyses were performed separately for males and females. All analyses were performed using SAS[®] release 9.1. For the RECPAM analysis, we used an SAS macroroutine written by F. Pellegrini. *p* values <0.05 were considered significant.

Results

Study population

From January, 2006, to March, 2007, 1,129 patients were admitted consecutively to the Geriatric Unit of "Casa Sollievo della Sofferenza" Hospital in San Giovanni Rotondo (FG). Of the 1,129 patients assessed for eligibility, 72 patients were excluded because they were younger than 65 years, and 28 refused to participate. Because only 7 patients had a BMI value less than 18.5, they were excluded from the analysis. Thus, 1,022 patients (494 men and 528 women) with a mean age of 77.6 ± 6.7 years (range 65–100 years), were eligible for the present investigation. Table 1 reports the characteristics of patients included in the study, divided according to gender. Female patients had significantly higher BMI mean values, higher serum TC, LDL-C, and HDL-C concentrations, and a higher prevalence of hypertension than male patients ($p=0.0001$). Age, serum TG concentration, and the prevalence of diabetes mellitus and AD were not significantly different between male and female patients. The distribution of the different APOE polymorphisms among all subjects was as follows: 11.5% for the $\epsilon 2/\epsilon 3$ genotype ($n=118$), 71.2% for the $\epsilon 3/\epsilon 3$ genotype ($n=728$), 15.3% for the $\epsilon 3/\epsilon 4$ genotype ($n=157$), 0.88% for the $\epsilon 4/\epsilon 4$ genotype ($n=9$), and 0.9% for the $\epsilon 2/\epsilon 4$ genotype ($n=10$). No $\epsilon 2/\epsilon 2$ APOE genotypes were observed. Patients with the $\epsilon 2/\epsilon 4$ genotype ($n=10$) were not considered in the analysis. The observed genotype

frequency distributions did not show statistically significant differences compared with those expected under Hardy-Weinberg equilibrium ($p=0.106$). Estimated allele frequencies were 0.062 for the $\epsilon 2$ allele, 0.846 for the $\epsilon 3$ allele, and 0.085 for the $\epsilon 4$ allele. The distribution of the APOE genotype frequencies was not significantly different between males and females (Table 1).

Table 2 shows the mean levels of serum lipids in patients, divided according to BMI and gender. The effect of BMI on serum lipid concentrations was studied by using BMI classes (normal weight, overweight, and obese). The mean value of BMI in the general population is 27.5 ± 5.1 kg/m²; 336 (33.2%) patients were normal weight, 399 (39.4%) were overweight, and 277 (27.4) were obese according to their baseline BMI. In both male and female patients, BMI was significantly associated with serum concentrations of TC and LDL-C, but not with HDL-C. BMI was significantly associated with serum concentration of TG only in males.

APOE polymorphism, plasma lipid, lipoprotein concentrations, and BMI

The bioclinical characteristics according to APOE polymorphisms are summarized in Table 3. No difference in the mean age of the patients across the APOE polymorphisms was observed. In both male and female patients, the mean concentrations of TC and LDL-C were APOE genotype dependent; APOE $\epsilon 4$ carriers had significantly higher levels of TC and LDL-C compared to $\epsilon 2$ and $\epsilon 3$ carriers. In contrast, there were no significant differences among APOE genotypes in plasma concentrations of HDL-C and TG. The effect of APOE alleles on BMI was studied by using BMI as a continuous variable or by using BMI classes (normal weight, overweight, and obese). In both male and female patients,

TABLE 1. BASELINE CHARACTERISTICS OF PATIENTS DIVIDED ACCORDING TO GENDER

	Total (n = 1022)	Men (n = 494)	Women (n = 528)	p
Mean age (years, mean $\pm$ SD)	77.6 $\pm$ 6.7	77.4 $\pm$ 6.7	77.7 $\pm$ 6.7	0.490
BMI ^a (kg/m ² , mean $\pm$ SD)	27.5 $\pm$ 5.1	26.7 $\pm$ 4.3	28.3 $\pm$ 5.6	0.000
Diabetes mellitus ^a	206 (20.1)	92 (18.6)	114 (21.6)	0.274
Hypertension ^a	411 (40.2)	161 (32.6)	250 (47.3)	0.000
Ischemic cardiomyopathy ^a	87 (8.5)	54 (10.9)	33 (6.2)	0.007
Alzheimer dementia	180 (17.8)	83 (17.0)	97 (18.5)	0.532
Total cholesterol ^b	165.9 $\pm$ 45.7	158.4 $\pm$ 44.0	173.5 $\pm$ 45.9	0.000
LDL-C ^b	100.9 $\pm$ 36.7	95.9 $\pm$ 36.7	105.6 $\pm$ 36.0	0.000
HDL-C ^b	39.5 $\pm$ 14.9	37.1 $\pm$ 13.5	41.8 $\pm$ 15.8	0.000
Triglycerides (TG) ^b	119.1 $\pm$ 66.5	115.3 $\pm$ 62.9	122.6 $\pm$ 69.5	0.083
Allele frequencies (%)				
$\epsilon 3$ (%)	84.6	84.6	85.4	0.657
$\epsilon 4$ (%)	8.5	8.1	9.9	0.180
$\epsilon 2$ (%)	6.2	7.1	5.4	0.134
Genotype frequencies				
$\epsilon 3/\epsilon 3$ ^a	728 (71.2)	349 (70.6)	379 (71.7)	0.749
$\epsilon 2/\epsilon 3$ ^a	118 (11.5)	65 (13.1)	53 (10.0)	0.148
$\epsilon 4/\epsilon 3$ ^a	157 (15.3)	73 (14.8)	84 (15.9)	0.688
$\epsilon 4/\epsilon 4$ ^a	9 (0.88)	1 (0.2)	8 (1.5)	0.140
$\epsilon 2/\epsilon 4$ ^a	10 (0.9)	6 (1.2)	4 (0.7)	0.615
1 year mortality ^a	161 (15.9)	94 (19.3)	67 (12.8)	0.005

^aData are N° (%).

^bData are mg/dL.

SD, Standard deviation; BMI, body mass index; LDL-C, low-density lipoprotein cholesterol; HDL-C high-density lipoprotein.

TABLE 2. LIPID LEVELS IN PATIENTS DIVIDED ACCORDING TO BMI CLASSES

	Men (n = 488)				Women (n = 524)			
	Normal weight (n = 180)	Overweight (n = 208)	Obese (n = 100)	p	Normal weight (n = 156)	Overweight (n = 191)	Obese (n = 177)	p
TC	152.1 ± 42.4	159.1 ± 44.5	165.9 ± 44.3	0.038 ^a	164.3 ± 43.8	179.9 ± 46.0	174.3 ± 47.3	0.007 ^a
TG	101.2 ± 47.7	122.3 ± 66.0	123.1 ± 70.1	0.001 ^b	115.7 ± 73.4	117.6 ± 60.1	131.8 ± 69.1	0.054 ^b
HDL-C	38.2 ± 14.7	36.3 ± 13.7	36.9 ± 10.5	0.392	43.2 ± 17.4	41.1 ± 13.5	41.6 ± 16.9	0.462
LDL-C	91.1 ± 35.9	96.3 ± 38.5	103.1 ± 36.7	0.033 ^c	96.8 ± 35.8	111.2 ± 35.6	107.6 ± 34.8	0.001 ^c

Data are mean ± standard deviation (SD), mg/dL.

^aMen: normal weight vs. obese, $p = 0.036$; women: normal weight vs. overweight, $p = 0.005$.

^bMen: normal weight vs. overweight, $p = 0.002$; normal weight vs. obese, $p = 0.013$.

^cMen: normal weight vs. obese, $p = 0.028$; women: normal weight vs. overweight, $p = 0.001$; normal weight vs. obese, $p = 0.020$.

BMI, body mass index; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.

there was no significant difference among APOE genotypes between normal-weight, overweight, and obese patients (Table 3).

Mortality data

A total of 161 deaths (15.9%) occurred during the follow up. Males had significantly higher mortality rates than females (19.3% vs. 12.8%, $p = 0.005$). Female patients who died had significantly lower mean BMI than female patients who survived (BMI = 26.8 ± 5.2 vs. 28.5 ± 5.7 , $p = 0.018$); this difference was not found in male patients (BMI = 26.1 ± 4.3 vs. 26.8 ± 4.2 , $p = 0.118$). Mortality was significantly higher in normal weight patients than obese patients both in males (40.4% vs. 20.2%, p for trend = 0.001) and female (41.8% vs. 25.4%; p for trend = 0.001). Male patients who died had a significantly lower level of LDL-C (85.8 ± 38.5 vs. 98.2 ± 35.9 ; $p = 0.003$) and HDL-C (34.5 ± 15.4 vs. 37.7 ± 12.9 ; $p = 0.041$) than patients who survived, whereas TC (151.1 ± 47.0 vs. 159.5 ± 43.1 ; $p = 0.095$) and TG levels (118.4 ± 67.4 vs. 113.8 ± 60.2 ; $p = 0.540$) did not differ significantly. In female patients, levels of TC (147.6 ± 47.7 vs. 177.16 ± 44.7 ; $p = 0.000$), LDL-C (92.8 ± 36.8 vs. 107.6 ± 35.4 ; $p = 0.002$), and

HDL-C (37.3 ± 14.7 vs. 42.6 ± 15.9 ; $p = 0.016$) were significantly lower in patients who died compared to survivors. The APOE $\epsilon 2$ carriers had lower mortality compared with APOE $\epsilon 3$ and $\epsilon 4$ carriers both in males (8.5% vs. 75.5% vs. 16%) and females (6% vs. 80.6% vs. 13.4%) (Table 4). No significant differences in the prevalence of AD were observed between patients who died versus survivors.

Multivariate logistic regression analysis, adjusted for several confounding factors, indicates that obesity (OR = 0.486, 95% CI 0.255–0.927, $p = 0.028$), TC > 180 mg/dL (OR = 0.350, 95% CI 0.187–0.657, $p = 0.001$), and LDL-C > 100 mg/dL (OR = 0.456, 95% CI 0.235–0.882; $p = 0.020$) are factors significantly associated with a lower risk of mortality in female patients. These associations were not observed in male patients. No significant association between APOE genotype, higher TG, lower HDL-C level, and 1-year mortality was observed (Table 5).

Interactions

To investigate the interaction between APOE genotype, BMI, lipid levels, and mortality, a RECPAM analysis was performed separately for males and females leading to the

TABLE 3. SERUM LIPID LEVELS AND BMI DISTRIBUTION IN PATIENTS DIVIDED ACCORDING TO THEIR APOE ALLELE STATUS

	Men				Women			
	$\epsilon 2/$ (n = 65)	$\epsilon 3/\epsilon 3$ (n = 349)	$\epsilon 4/$ (n = 74)	p	$\epsilon 2/$ (n = 53)	$\epsilon 3/\epsilon 3$ (n = 379)	$\epsilon 4/$ (n = 92)	p
Age	77.9 ± 6.9	77.2 ± 6.6	78.3 ± 6.6	0.360	77.2 ± 6.5	77.9 ± 6.7	77.4 ± 6.5	0.671
TC ^a (mg/dL)	141.8 ± 42.5	159.4 ± 42.2	164.9 ± 50.1	0.004 ^b	164.8 ± 51.4	172.1 ± 45.1	183.4 ± 46.0	0.039
TG ^a (mg/dL)	116.8 ± 71.9	115.9 ± 57.6	106.8 ± 69.8	0.489	116.5 ± 57.1	118.9 ± 63.1	136.9 ± 87.7	0.061
HDL-C ^a (mg/dL)	36.5 ± 11.9	36.6 ± 13.4	39.8 ± 15.0	0.183	40.8 ± 15.2	42.4 ± 14.5	40.3 ± 21.7	0.472
LDL-C ^a (mg/dL)	80.7 ± 34.9	97.7 ± 36.2	100.8 ± 38.0	0.001 ^c	90.8 ± 33.9	106.9 ± 34.7	109.5 ± 35.8	0.006 ^c
BMI ^a (kg/m ²)	26.9 ± 3.7	26.8 ± 4.3	26.1 ± 4.3	0.419	28.9 ± 5.6	28.3 ± 5.6	27.9 ± 6.2	0.639
Normalweight ^d	19 (29.2)	129 (37.0)	32 (43.2)	0.088	15 (28.3)	111 (29.3)	30 (32.6)	0.534
Overweight ^d	33 (50.8)	146 (41.8)	29 (39.2)	0.178	17 (32.1)	141 (37.2)	33 (35.9)	0.755
Obese ^d	13 (20.0)	74 (21.2)	13 (17.6)	0.698	21 (39.3)	127 (33.5)	29 (31.5)	0.358

^aData are mean ± standard deviation.

^bMen: $\epsilon 2$ vs. $\epsilon 3/$ $\epsilon 3$, $p = 0.009$; $\epsilon 2$ vs. $\epsilon 4$, $p = 0.006$.

^cMen: $\epsilon 2$ vs. $\epsilon 3/$ $\epsilon 3$, $p = 0.002$; $\epsilon 2$ vs. $\epsilon 4$, $p = 0.004$; women: $\epsilon 2$ vs. $\epsilon 3/$ $\epsilon 3$, $p = 0.008$; $\epsilon 2$ vs. $\epsilon 4$, $p = 0.009$.

^dData are N° (%).

BMI, body mass index; APOE, apolipoprotein E; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.

TABLE 4. BASELINE CHARACTERISTICS OF MEN AND WOMEN BY VITAL STATUS

	Men			Women		
	Survivors (n = 394)	Decedents (n = 94)	p	Survivors (n = 457)	Decedents (n = 67)	P
BMI ^a (kg/m ²)	26.8 ± 4.2	26.1 ± 4.3	0.118	28.5 ± 5.7	26.8 ± 5.2	0.018
Normal weight ^b	142 (36.0)	38 (40.4)		128 (28.0)	28 (41.8)	
Overweight ^b	171 (43.4)	37 (39.4)		169 (37.0)	22 (32.8)	
Obese ^b	81 (20.6)	19 (20.2)	<i>p</i> for trend 0.001	160 (35.0)	17 (25.4)	<i>p</i> for trend 0.003
Alzheimer disease ^b	73 (18.5)	10 (10.6)		88 (19.3)	9 (13.4)	
ε2 carrier ^b	57 (14.5)	8 (8.5)	0.127	49 (10.7)	4 (6)	0.228
ε3 carrier ^b	273 (70.6)	71 (75.5)	0.337	325 (71.1)	54 (80.6)	0.105
ε4 carrier ^b	59 (15)	15 (16)	0.811	83 (18.2%)	9 (13.4)	0.342
TC ^a (mg/dL)	159.5 ± 43.1	151.1 ± 47.0	0.095	177.16 ± 44.7	147.6 ± 47.7	0.000
LDL-C ^a (mg/dL)	98.2 ± 35.9	85.8 ± 38.5	0.003	107.6 ± 35.4	92.8 ± 36.8	0.002
HDL-C ^a (mg/dL)	37.7 ± 12.9	34.5 ± 15.4	0.004	42.6 ± 15.9	37.3 ± 14.7	0.016
TG ^a (mg/dL)	113.8 ± 60.2	118.4 ± 67.4	0.540	120.9 ± 64.8	128.4 ± 85.4	0.394

^aData are mean ± standard deviation.

^bData are N° (%).

BMI, Body mass index; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides.

identification of five classes of patients at different risk of mortality (Fig. 1A,B). The reference category was represented by the subgroup with the lowest mortality. Thus, the ORs for all the other subgroups were estimated with respect to the reference class.

In females, the most important variable in discriminating the risk of death was represented by the TC, with the lowest mortality in patients with values of TC greater than 180 mg/dL. On the opposite side of the regression tree, patients APOE ε3 carriers, LDL-C values lower than 100 mg/dL and with a normal weight represented the subgroup with the

highest mortality (OR = 3.42, 95% CI = 1.36–8.60). The class of patients with TC lower than 180 mg/dL APOE ε3 carrier but with LDL-C greater than 100 mg/dL showed a significant risk of mortality (OR = 2.59, 95% CI 1.09–6.18). For patients showing a TC lower than 180 mg/dL, APOE ε3 carrier, a LDL-C lower than 100 mg/dL but overweight or obese, the estimated OR = 3.17 (95% CI 1.42–7.08). Patients' age ($p < 0.001$) and presence of diabetes ($p = 0.70$), AD, and cardiovascular diseases ($p = 0.47$) were included in the model as global adjustment variables.

In males, the class of patients with lowest mortality were those with LDL-C higher than 100 mg/dL and overweight or obese. On the opposite side of the regression tree, patients with LDL-C lower than 100 mg/dL, HDL lower than 40 mg/dL, and APOE ε3 carrier showed the highest mortality (OR = 1.97, 95% CI 1.04–3.74). Patients' age ($p = 0.057$), presence of diabetes ($p = 0.175$), AD, and cardiovascular disease ($p = 0.062$) were included in the model as global adjustment variables.

TABLE 5. RISK FACTOR FOR 1-YEAR MORTALITY ACCORDING TO GENDER

	OR (95% CI)	
	Men	Women
Normal weight	1 (reference)	1 (reference)
Overweight	0.809 (0.488–1.339)	0.595 (0.325–1.088) ^a
Obese	0.877 (0.474–1.621)	0.486 (0.255–0.927) ^a
ε2 carrier	0.598 (0.270–1.104)	0.323 (0.094–1.119) ^b
ε3 carrier	1 (reference)	1 (reference)
ε4 carrier	1.024 (0.542–1.936)	0.883 (0.404–1.931) ^b
Hypercholesterolemia	0.819 (0.488–1.374)	0.350 (0.187–0.657) ^c
High LDL-C	0.860 (0.496–1.492)	0.456 (0.235–0.882) ^c
High TG	1.197 (0.673–2.130)	1.316 (0.675–2.568) ^d
Lower HDL-C	1.640 (0.778–3.458)	1.338 (0.768–2.330) ^e

^aData were adjusted for age, diabetes, dyslipidemia, and cardiovascular disease.

^bData were adjusted for total-cholesterol and LDL-C levels and Alzheimer disease.

^cData were adjusted for age, BMI, cardiovascular disease; APOE genotype.

^dData were adjusted for age, BMI, and diabetes.

^eData were adjusted for age and cardiovascular disease.

OR, Odds ratio; CI, confidence interval; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; BMI, body mass index; APOE, apolipoprotein E.

Discussion

The detection of gene–environment interactions can provide key information on the biological mechanisms of diseases and can lead to new insights into the prevention, diagnosis, and treatment of chronic diseases in specific subgroups of the population. In this study, we evaluated the relationship among APOE polymorphism, BMI, and dyslipidemia and how these factors modify overall mortality risk. In agreement with previous studies,^{19,20} we found that the mean concentrations of TC and LDL-C were APOE genotype and BMI dependent in both male and female elderly patients. In this study, TC and LDL-C levels were significantly higher in obese than in normal weight patients, and in subjects carrying ε4 compared to subjects carrying ε2 and ε3 in both males and females patients. In contrast, we did not find a significant association between APOE alleles and serum HDL-C concentrations in both men and women. A significant association between APOE polymorphism and HDL-C

FIG. 1. Identification of subgroups at different risks for mortality: Results of RECPAM analysis. RECPAM analysis identified patient subgroups at different risks for mortality. The tree-growing algorithm modeled odds ratios (OR) after a logistic regression with age, diabetes, and ischemic cardiomyopathy as global variables. Splitting variables are shown between branches, whereas a condition sending patients to left or right sibling is on a relative branch. Class 1 with lowest mortality was the reference category (OR = 1). Circles indicate subgroups of patients; squares indicate the patient subgroup RECPAM class. Numbers inside circles and squares represent the number of events (*top*) and the number of nonevents (*bottom*), respectively. (A) Females. Global adjustment variables: Age OR = 1.11 (1.06–1.16), diabetes OR = 1.15 (0.57–2.34), ischemic cardiomyopathy OR = 0.71 (0.28–1.81). (B) Males. Global adjustment variables: Age OR = 1.03 (1.00–1.07), diabetes OR = 1.59 (0.81–3.08), ischemic cardiomyopathy OR = 0.52 (0.26–1.03).

has been reported in some studies²¹ but not in others.²² Discrepancies among different studies may be due to other factors that regulate the gene–environment interaction affecting HDL-C levels, such as physical activity, alcohol consumption, and smoking.

In this population, no significant association between APOE polymorphism and obesity was found. Only a few studies have examined the relationship between APOE polymorphisms and obesity. Although a significant association between APOE $\epsilon 4$ allele status and obesity was reported in children and young adults,²³ other studies failed to find a

significant difference in the APOE allele and genotype frequencies between obese and nonobese subjects.²⁴ In addition, none of these studies included hospitalized elderly patients. A possible explanation for the lack of association between BMI and APOE polymorphism in our population is that BMI may be a poor indicator of obesity in elderly persons because body composition varies with age.

In addition, we found that, unlike in nonelderly patients, higher levels of TC in females and LDL-C in males are associated with a lower risk of mortality. This paradoxical result is in line with previous reports showing that

hypercholesterolemia is associated with lower mortality in elderly patients.^{25–27} There are several potential explanations for these findings. It is possible that subjects with higher cholesterol levels died before recruitment and that the sample represents a group of healthy survivors with traits that make them less susceptible to disease caused by high cholesterol levels. Moreover, it is well known that cholesterol levels decrease with age, and it has been suggested that low cholesterol levels in the elderly represent a surrogate marker of frailty or subclinical disease.²⁸

In the present study, multivariate regression analysis shows a negative relationship between BMI and mortality; and the interaction analysis revealed that overweight and obesity are protective in both males and females, even if with a different grade of interaction, as suggested by the different composition of the RECPAM tree-based algorithm, adjusted for age, diabetes, and AD or cardiovascular disease. These findings are in agreement with previous studies.^{29–31} Several hypotheses have been made to explain this effect of BMI on mortality in the elderly: (1) The relationship among BMI, body fat, and fat distribution weaken with aging; (2) lean mass and fat mass act as important nutritional reserve during prolonged illness and may be particularly important in old age as the incidence and significance of illness and disease increase; (3) individuals susceptible to the ill effects of elevated BMI may have already died, determining a selective survival.

This study has limitations. First, our study evaluated the interaction among APOE polymorphisms, BMI, dyslipidemia, and mortality risk, but did not evaluate the serum concentrations of APOE, which has been shown to influence the levels of circulating lipids.³² Second, in our study, we used BMI as marker of obesity, instead of waist circumference or trunk fat mass measured by dual-energy X-ray absorptiometry (DEXA), which are better predictors of mortality in old age.³³ Finally, the use of hospitalized elderly patients does not allow us to exclude that demographic selection could play a role in the reported differences. In conclusion, in elderly hospitalized patients, obesity and APOE genotype influence the lipid profile and mortality risk. A significant interaction among BMI, dyslipidemia, and APOE genotype was observed that could identify elderly patients with different risks of mortality.

Acknowledgments

This research was supported by grants from Ministero della Salute and IRCCS Research Program 2008–2010, Line 2: “Malattie di rilevanza sociale” and was supported in part by the Intramural Research Program of the National Institutes of Health, National Institute on Aging.

Author Disclosure Statement

None of the authors has any conflict of interest associated with the work presented in this manuscript. All authors had access to the data and played a role in writing this manuscript.

References

- Denke MA, Sempos CT, Grundy SM. Excess body weight: An under-recognized contributor to dyslipidemia in white American women. *Arch Intern Med* 1994;154:401–10.
- Mahley RW. Apolipoprotein E: Cholesterol transport protein with expanding in cell biology. *Science* 1998;240:622–630.
- Grönroos P, Raitakari OT, Kähönen M, Hutri-Kähönen N, Marniemi J, Viikari J, Lehtimäki T. Influence of apolipoprotein E polymorphism on serum lipid and lipoprotein changes: a 21-year follow-up study from childhood to adulthood. The Cardiovascular Risk in Young Finns Study. *Clin Chem Lab Med* 2007;45:592–598.
- Ward H, Mitrou PN, Bowman R, Luben R, Wareham NJ, Khaw KT, Bingham S. APOE genotype, lipids, and coronary heart disease risk: A prospective population study. *Arch Intern Med* 2009;169:1424–1429.
- Zannis VI. Genetic polymorphism in human apolipoprotein E. *Methods Enzymol* 1986;95:2358–2367.
- Bennet AM, Di Angelantonio E, Ye Z, Wensley F, Dahlin A, Ahlbom A, Keavney B, Collins R, Wiman B, de Faire U, Danesh J. Association of apolipoprotein E genotype with lipid levels and coronary risk. *JAMA* 2007; 298:1300–1311.
- Corbo RM, Scacchi R. Apolipoprotein E (APOE) allele distribution in the world. Is APOE e4 a ‘thrifty’ allele?. *Ann Hum Genet* 1999;63:301–310.
- Sudlow C, Martinez Gonzalez NA, Kim J, Clark C. Does apolipoprotein E genotype influence the risk of ischemic stroke, intracerebral hemorrhage, or subarachnoid hemorrhage? Systematic review and meta-analysis of 31 studies among 5961 cases and 17965 controls. *Stroke* 2006;37:364–370.
- Orsitto G, Seripa D, Panza F, Franceschi M, Cascavilla L, Placentino G, Matera MG, Paris F, Capurso C, Solfrizzi V, Dallapiccola B, Pilotto A. Apolipoprotein E genotypes in hospitalized elderly patients with vascular dementia. *Dement Geriatr Cogn Dis* 2007;23:327–333.
- Seripa D, Panza F, Franceschi M, D’Onofrio G, Solfrizzi V, Dallapiccola B, Pilotto A. Non-apolipoprotein E and apolipoprotein E genetics of sporadic Alzheimer’s disease. *Ageing Res Rev* 2009;8:214–236.
- Fillenbaum GG, Burchett BM, Lee JH, Blazer DG. Mortality and apolipoprotein E in African-American, and White elders: An attempted replication. *Am J Med Genet* 2003;119A: 141–146.
- Hayden KM, Zandi PP, Lyketsos CG, Tschanz JT, Norton MC, Khachaturian AS, Pieper CF, Welsh-Bohmer KA, Breitner JC; Cache County Investigators. Apolipoprotein E genotype and mortality: findings from the Cache County Study. *J Am Geriatr Soc* 2005;53:935–942.
- Slooter AJ, Cruts M, Van Broeckhoven C, Hofman A, van Duijn CM. Apolipoprotein E and longevity: The Rotterdam Study. *J Am Geriatr Soc* 2001;49:1258–1259.
- Heijmans BT, Slagboom PE, Gussekloo J, Droog S, Lagaay AM, Kluft C, Knook DL, Westendorp RG. Association of APOE epsilon2/epsilon3/epsilon4 and promoter gene variants with dementia but not cardiovascular mortality in old age. *Am J Med Genet* 2002;107:201–208.
- McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnoses of Alzheimer’s disease: Report of NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. *Neurology* 1984;34:939–944.
- Clinical Guidelines on the Identification, Evaluation and Treatment of Overweight and Obesity in Adults. Bethesda, MD: National Heart, Lung and Blood Institute; 1998.
- Seripa D, Signori E, Gravina C, Matera MG, Rinaldi M, Fazio VM. Simple and effective determination of apolipoprotein E

- genotypes by positive/negative polymerase chain reaction products. *Diagn Mol Pathol* 2006;15:180–185.
18. Ciampi A, Negassa A, Lou Z. Tree-structured prediction for censored survival data and the Cox model. *J Clin Epidemiol* 1995;48:675–689.
 19. Marques-Vidal P, Bongard V, Ruidavets JB, Fauvel J, Hanaire-BROUTIN H, Perret B, Ferrières J. Obesity and alcohol modulate the effect of apolipoprotein E polymorphism on lipids and insulin. *Obes Res* 2003;11:1200–1206.
 20. Srinivasan SR, Ehnholm C, Elkasabany A, Berenson GS. Apolipoprotein E polymorphism modulates the association between obesity and dyslipidemias during young adulthood: The Bogalusa Heart Study. *Metabolism* 2001;50:696–702.
 21. Ikewaki K, Rader DJ, Zech LA, Brewer Jr HB. In vivo metabolism of apolipoproteins A-I and E in patients with abetalipoproteinemia: Implications for the roles of apolipoproteins B and E in HDL metabolism. *J Lipid Res* 1994;35:1809–1819.
 22. Martin LJ, Connelly PW, Nancoo D, Wood N, Zhang ZJ, Maguire G, Quinet E, Tall AR, Marcel YL, McPherson R. Cholesteryl ester transfer protein and high density lipoprotein responses to cholesterol feeding in men: Relationship to apolipoprotein E genotype. *J Lipid Res* 1993;34:437–446.
 23. Srivastava N, Achyut BR, Prakash J, Agarwal CG, Pant DC, Mittal B. Association of cholesteryl ester transfer protein (TaqIB) and apolipoprotein E (HhaI) gene variants with obesity. *Mol Cell Biochem* 2008;314:171–177.
 24. Eto M, Watanabe K, Ishii K. Apolipoprotein E polymorphism and hyperlipoproteinemia in obesity. *Int J Obes* 1989;13:433–440.
 25. Tikhonoff V, Casiglia E, Mazza A, Scarpa R, Thijs L, Pessina AC, Staessen JA. Low-density lipoprotein cholesterol and mortality in older people. *J Am Geriatr Soc* 2005;53:2159–2164.
 26. Schupf N, Costa R, Luchsinger J, Tang MX, Lee JH, Mayeux R. Relationship between plasma lipids and all cause mortality in non demented elderly. *J Am Geriatr Soc* 2005;53:219–226.
 27. Chyou P, Eaker ED. Serum cholesterol concentrations and all cause mortality in older people. *Age Ageing* 2000;29:69–74.
 28. Schalk BW, Visser M, Deeg DJ, Bouter LM. Lower levels of serum albumin and total cholesterol and future decline in functional performance in older persons: The Longitudinal Aging Study Amsterdam. *Age Ageing* 2004;33:266–272.
 29. Adams KF, Schatzkin A, Harris TB, Kipnis V, Mouw T, Ballard-Barbash R, Hollenbeck A, Leitzmann MF. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. *N Engl J Med* 2006;355:763–778.
 30. Janssen I, Mark AE. Elevated body mass index and mortality risk in the elderly. *Obes Rev* 2007;8:41–59.
 31. Janssen I. morbidity and mortality risk associated with an overweight BMI in older men and women. *Obesity* 2007;15:1827–1840.
 32. Haddy N, De Bacquer D, Chemaly MM, Maurice M, Ehnholm C, Evans A, Sans S, Do Carmo Martins M, De Backer G, Siest G, Visvikis S. The importance of plasma apolipoprotein E concentration in addition to its common polymorphism on inter-individual variation in lipid levels: Results from APO Europe. *Eur J Hum Gen* 2002;10:841–850.
 33. Price GM, Uauy R, Breeze E, Bulpitt CJ, Fletcher AE. Weight, shape, and mortality risk in older persons: elevated waist-hip ratio, not high body mass index, is associated with a greater risk of death. *Am J Clin Nutr* 2006;84:449–460.

Address correspondence to:

Alberto Pilotto, M.D.

Geriatric Unit & Gerontology-Geriatrics Research Laboratory

Department of Medical Sciences

IRCCS Casa Solievo della Sofferenza

Viale Cappuccini 1

San Giovanni Rotondo (FG)

Italy

E-mail: alberto.pilotto@operapadrepio.it

Received: April 13, 2010

Accepted: May 14, 2010